Antisense Oligonucleotide Emulsion for Corneal Neovascularization
Solution Overview
Problem
Conventional therapies for inhibiting corneal neovascularization, such as corticosteroids and immunosuppressants, are only partially effective and have significant side effects, necessitating an alternative approach for preventing and treating blood and lymph vascularization in the eyes.
Innovation Solution
A pharmaceutical composition containing an antisense oligonucleotide GS-101, formulated as an oil-in-water emulsion with specific concentrations and components, is administered topically to inhibit IRS-1 expression and prevent or stabilize blood and lymph vascularization, suitable for treating conditions like corneal graft rejection and age-related macular degeneration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional therapies (corticosteroids and immunosuppressants) are used to inhibit corneal neovascularization, then some therapeutic effect is achieved, but side effects increase and effectiveness is limited
Solution Approach 1:
The patent changes the therapeutic parameter from conventional corticosteroids/immunosuppressants to antisense oligonucleotide GS-101, which specifically targets IRS-1 gene expression. This molecular-level parameter change enables selective inhibition of neovascularization pathways while avoiding the broad immunosuppression side effects of conventional therapies
Solution Approach 2:
The antisense oligonucleotide GS-101 acts as an intermediary molecule that binds to IRS-1 mRNA, preventing its translation into protein. This intermediary mechanism specifically blocks the signaling pathway involved in neovascularization without affecting other immune functions, thereby reducing side effects while maintaining therapeutic effectiveness
2Reliability
If higher concentrations of antisense oligonucleotide are used to improve therapeutic effect, then efficacy increases, but formulation stability and tolerability may be compromised
Solution Approach 1:
The patent formulates GS-101 as an oil-in-water emulsion containing multiple components (oil phase, aqueous phase, surfactants, stabilizers) that work synergistically. This composite formulation enables high concentrations of antisense oligonucleotide to be maintained stably over time while remaining tolerable for ocular administration
Solution Approach 2:
The patent optimizes multiple formulation parameters including pH, osmolality, surfactant concentration, and emulsion droplet size to achieve a stable formulation that can accommodate high GS-101 concentrations. These parameter adjustments ensure both formulation stability and ocular tolerability at therapeutic doses
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition effectively inhibits corneal neovascularization, reduces the risk of immune rejection after corneal grafting, and treats conditions like glaucoma, diabetic retinopathy, and age-related macular degeneration by reducing neovascularization, demonstrating safety and efficacy in clinical trials.
Implementation Method 1
a pharmaceutical composition comprising as active agent, an antisens oligonucleotide having the sequence SEQ ID NO: 1, wherein said antisens oligonucleotide is in a concentration from about 0.40 mg/ml to about 2 mg/ml
Data Source
AI summary
A pharmaceutical composition including as active agent, an antisens oligonucleotide having the sequence SEQ ID NO: 1, wherein the antisens oligonucleotide is in a concentration from about 0.40 mg/ml to about 2 mg/ml and the use thereof for preventing, stabilizing and/or inhibiting blood and lymph vascularization.